BioNTech and Gilead announce clinical trial collaboration for triple-negative breast cancer

BioNTech SE and Gilead Sciences announced a clinical trial collaboration and supply agreement to study the combination of BioNTech's Pumitamig and Gilead's TROP2-directed antibody-drug conjugate Sacituzumab Govitecan as a first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer with low or negative PD-L1 expression.

Detected & updated continuously · Source: Nebula